CHF 40,000 for injectable microcushions for damaged joints, targetted enzyme therapies, and interactive AI movies
13.10.2025
Eldian Biomed, NanoZymeX, and OOVIE Studios were selected at Venture Kick's second financial and entrepreneurial support stage. Their projects develop a patented microcushion technology of lipid nanoparticles crosslinked with peptide linkers; deliver enzyme therapies precisely where they are needed; and transform the visions of the musicians into interactive AI movies, crafted by world-renowned AI artists.
 |
 |
 Eldian Biomed: CEO Gregor Bordon
|
|
 NanoZymeX: Margarita C. Dinamarca & Boris Sevarika
|
|
 OOVIE Studios: CAO & Sales Giulio Casagrande, CTO Ignacio Palladino, CEO Riccardo Acciarino, CMO Lorenzo Ramon, and COO Marco Seco
|
|
Eldian Biomed: Injectable Microcushions for Damaged Joints
Osteoarthritis (OA) affects over 500 million people and is a leading cause of disability. Current treatments offer only temporary relief and fail to stop disease progression, underscoring the need for disease-modifying solutions.
Eldian Biomed, a spin-off from the University of Bern, is developing CloudLi—a patented microcushion technology of lipid nanoparticles crosslinked with peptide linkers, targeting both inflammation and cartilage wear. In animal models, CloudLi showed marked improvements in joint structure and well-being. The team is led by Gregor Bordon, supported by the research infrastructure of the University of Bern, including the labs of Prof. Paola Luciani and Prof. Jean Louis Reymond. The OA therapy market is projected to reach USD 17B by launch, with CloudLi addressing a USD 1–1.4B segment for non-end-stage knee OA in Europe and the US.
Venture Kick funding will support trademark filings, website setup, and presence at key investor conferences ahead of a 2026 raise.
NanoZymeX: Delivering enzyme therapies precisely where they are needed
NanoZymeX is a health startup project developing a new therapy for rare genetic conditions known as lysosomal storage diseases. Their innovative approach uses lipid-based nanoparticles to deliver therapeutic enzymes directly into cells, helping the body break down harmful substances more effectively. Current treatments for lysosomal storage diseases often struggle to get the needed enzymes into the right parts of the body, especially inside cells where they’re needed most. As a result, patients face frequent, high-dose infusions with limited efficacy and high risk of immune responses.
The startup project is led by Boris Sevarika and Margarita C. Dinamarca, based at the University of Basel within the Nanopharmaceutical and Regulatory Science Group of Professor Scott McNeil. The team is developing a lipid nanoparticle-based enzyme delivery platform that encapsulates therapeutic enzymes and delivers them to the place in the body where they are needed. The first target is Pompe disease, a rare neuromuscular disorder with a global market exceeding USD 2 billion, but the platform is adaptable to a broad range of enzyme-driven indications in rare and metabolic diseases. This next-generation treatment aims to improve the lives of patients with these often-overlooked and difficult-to-treat disorders.
With Venture Kick support, the NanoZymeX team will refine its business model, conduct structured interviews with stakeholders to validate the solution, and expand its network of key opinion leaders in enzyme therapy and lysosomal storage disorders. These activities will position the project for incorporation and fundraising, laying a strong foundation for future growth.
OOVIE Studios: Interactive AI Movies that Change Every time you Watch them, Powered by Live Music and Human Interaction
Classical music struggles to engage younger and broader audiences, who seek more immersive, multimedia formats than traditional concerts.
Incorporated in May 2025 in Lugano by five co-founders – CEO Riccardo Acciarino, COO Marco Seco, CTO Ignacio Palladino, CAO & Sales Manager Giulio Casagrande, and CMO Lorenzo Ramon – OOVIE Studios transforms the visions of the musicians into interactive AI movies, crafted by world-renowned AI artists. The narrative changes every time automatically following the nuances of music and audience input. OOVIE bridges several markets with common needs, adapting its format for both the musical and corporate world. After launching its first immersive brand experience with EssilorLuxottica – EA7, the startup will premiere its launch tour with Grammy-winning violinist Maxim Vengerov during the Venice Film Festival, at the Trieste Festival, and Teatro Piccolo “Strehler” in Milan.
They will use the Venture Kick funds to organize a private client roadshow, register the trademark, and cover key team travel expenses for the launch tour.
Osteoarthritis (OA) affects over 500 million people and is a leading cause of disability. Current treatments offer only temporary relief and fail to stop disease progression, underscoring the need for disease-modifying solutions.
Eldian Biomed, a spin-off from the University of Bern, is developing CloudLi—a patented microcushion technology of lipid nanoparticles crosslinked with peptide linkers, targeting both inflammation and cartilage wear. In animal models, CloudLi showed marked improvements in joint structure and well-being. The team is led by Gregor Bordon, supported by the research infrastructure of the University of Bern, including the labs of Prof. Paola Luciani and Prof. Jean Louis Reymond. The OA therapy market is projected to reach USD 17B by launch, with CloudLi addressing a USD 1–1.4B segment for non-end-stage knee OA in Europe and the US.
Venture Kick funding will support trademark filings, website setup, and presence at key investor conferences ahead of a 2026 raise.
NanoZymeX: Delivering enzyme therapies precisely where they are needed
NanoZymeX is a health startup project developing a new therapy for rare genetic conditions known as lysosomal storage diseases. Their innovative approach uses lipid-based nanoparticles to deliver therapeutic enzymes directly into cells, helping the body break down harmful substances more effectively. Current treatments for lysosomal storage diseases often struggle to get the needed enzymes into the right parts of the body, especially inside cells where they’re needed most. As a result, patients face frequent, high-dose infusions with limited efficacy and high risk of immune responses.
The startup project is led by Boris Sevarika and Margarita C. Dinamarca, based at the University of Basel within the Nanopharmaceutical and Regulatory Science Group of Professor Scott McNeil. The team is developing a lipid nanoparticle-based enzyme delivery platform that encapsulates therapeutic enzymes and delivers them to the place in the body where they are needed. The first target is Pompe disease, a rare neuromuscular disorder with a global market exceeding USD 2 billion, but the platform is adaptable to a broad range of enzyme-driven indications in rare and metabolic diseases. This next-generation treatment aims to improve the lives of patients with these often-overlooked and difficult-to-treat disorders.
With Venture Kick support, the NanoZymeX team will refine its business model, conduct structured interviews with stakeholders to validate the solution, and expand its network of key opinion leaders in enzyme therapy and lysosomal storage disorders. These activities will position the project for incorporation and fundraising, laying a strong foundation for future growth.
OOVIE Studios: Interactive AI Movies that Change Every time you Watch them, Powered by Live Music and Human Interaction
Classical music struggles to engage younger and broader audiences, who seek more immersive, multimedia formats than traditional concerts.
Incorporated in May 2025 in Lugano by five co-founders – CEO Riccardo Acciarino, COO Marco Seco, CTO Ignacio Palladino, CAO & Sales Manager Giulio Casagrande, and CMO Lorenzo Ramon – OOVIE Studios transforms the visions of the musicians into interactive AI movies, crafted by world-renowned AI artists. The narrative changes every time automatically following the nuances of music and audience input. OOVIE bridges several markets with common needs, adapting its format for both the musical and corporate world. After launching its first immersive brand experience with EssilorLuxottica – EA7, the startup will premiere its launch tour with Grammy-winning violinist Maxim Vengerov during the Venice Film Festival, at the Trieste Festival, and Teatro Piccolo “Strehler” in Milan.
They will use the Venture Kick funds to organize a private client roadshow, register the trademark, and cover key team travel expenses for the launch tour.